Identity
- Security key
- 20249
- Ticker
- PMVP
- Type
- CS — Common Stock
- Exchange
- Nasdaq(XNAS)
- Venue group
- NASDAQ
- Operating MIC
- XNAS
- Market
- stocks
- Locale
- us
- Currency
- USD
- Listed
- 2020-09-25
- Round lot
- 100
- Active
- Yes
- Last seen in a load
- 2026-08-14 20:49
- Vendor updated
- 2026-08-13 06:09
- Ticker root / suffix
- PMVP
Detail
Enriched 2026-08-14 20:47
- Market cap
- $67,198,025.16
- Shares outstanding (class)
- 53,331,766
- Shares outstanding (weighted)
- 53,331,766
- SIC
- 2834 PHARMACEUTICAL PREPARATIONS
- Employees
- 54
- Location
- PRINCETON, NJ
- Homepage
- https://www.pmvpharma.com
- Description
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. The key product candidate, rezatapopt, is designed to be an orally available small molecule that structurally corrects the mutant p53 protein with the Y220C mutation. Currently, the product candidates are undergoing preclinical and clinical testing, and company relies on third parties for the manufacture after marketing approvals.
Market cap and share counts drift.